secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2026-05-15T11:05:36+00:00
Accession:  0001104659-26-061771
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Traws Pharma Q1 net loss $7.1M; secures up to $60M PIPE financing
-----------------------------------------------------------------

- Net loss of $7.1M ($0.53/share) vs net income of $21.5M in Q1 2025; revenue $0.
- R&D expense $4.9M (up 96% YoY) on antiviral trial milestones; cash $3.1M at March 31.
- Up to $60M private placement closed April 15 with $10M upfront, expected to fund ops into Q1 2027.
- TXM influenza prophylaxis advancing to human challenge trial in Q2 2026; FDA clinical hold unresolved.
- New hantavirus program initiated; no approved treatments exist for this disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465926061771/0001104659-26-061771-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465926061771/tm2614707d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-061771

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer